Agreed re the dumbness of the AbbVie name; moreover, I don’t even think the split-up per se will add shareholder value when all is said and done.
Still, the new Abbott (i.e. the current ABT minus AbbVie) will be a superb play on The Global Demographic Tailwind. I would go so far as to opine that it is a must-own core holding for anyone who is serious about this investing theme.
Market Data 
Markets 
AI
